Advocacy intelligence hub — real-time data for patient organizations
University Hospital, Caen
Peking University People's Hospital
Yartemlea: FDA approved
treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
Shahid Beheshti University — NA
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — NA
Peking University People's Hospital — PHASE2, PHASE3
Yi Zhang — NA
Yigeng Cao,MD,PhD — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs4
Yartemlea
(narsoplimab-wuug)Orphan drugOmeros Corporation
12.1 Mechanism of Action Narsoplimab-wuug inhibits MASP-2, the effector enzyme of the lectin pathway of the complement system, blocking lectin-depende...
Grafapex
(TREOSULFAN)Orphan drugMedexus Pharma, Inc.
Aphexda
(motixafortide)Orphan drugAyrmid Pharma Ltd.
12.1 Mechanism of Action Motixafortide is an inhibitor of the C-X-C Motif Chemokine Receptor 4 (CXCR4) and blocks the binding of its cognate ligand, s...
Defitelio
(defibrotide)Orphan drugstandardJazz Pharmaceuticals, Inc.
12.1 Mechanism of Action The mechanism of action of defibrotide sodium has not been fully elucidated. In vitro , defibrotide sodium enhances the enzym...
PREVYMIS
(letermovir)Orphan drugstandardMerck Sharp & Dohme LLC
Cytomegalovirus DNA Terminase Complex Inhibitor [EPC]
12.1 Mechanism of Action PREVYMIS is an antiviral drug against CMV [see Microbiology (12.4) ] .
Leukine
(Sargramostim)Orphan drugstandardImmunex Corporation
Leukocyte Growth Factor [EPC]
12.1 Mechanism of Action Sargramostim (GM-CSF) belongs to a group of growth factors termed colony-stimulating factors which support survival, clonal e...
A Significant Risk Factor for Post-Transplant Lymphoproliferative Disorder in Pediatric Recipients: Low CD3+CD4+ T Cell Count at 30 Days after Hematopoietic Stem Cell Transplantation.
Post-transplant lymphoproliferative disorder (PTLD) is a potentially life-threatening complication that arises early after pediatric hematopoietic stem cell transplantation (HSCT), primarily due to po...
Development and effectiveness evaluation of a mobile health-based follow-up management model for patients after hematopoietic stem cell transplantation.
To evaluate the association between mobile health (mHealth)-based follow-up and quality of life, self-management capacity, and complication control in patients after hematopoietic stem cell transplant...
Kidney and Blood Pressure Outcomes in Children Surviving at Least 6 Months after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Pediatric hematopoietic stem cell transplantation (HSCT) recipients are at risk of developing kidney and high blood pressure (BP) conditions, but the prevalence of these conditions is unclear. We aime...
Mineral disorders after hematopoietic stem cell transplantation in patients receiving parenteral nutrition.
Parenteral nutrition is a critical therapeutic approach for patients undergoing hematopoietic stem cell transplantation. However, parenteral nutrition is associated with complications such as mineral ...
Long-Term Health Outcomes in Male Survivors of Childhood Cancer After Hematopoietic Stem Cell Transplantation: A Registry-Based Study.
Late effects are a major concern after pediatric hematopoietic stem cell transplantation (HSCT), but data on health outcomes beyond early adulthood remain scarce. This study assessed long-term morbidi...
Risk factors for acute kidney injury after hematopoietic stem cell transplantation in children: a single-center retrospective study.
To analyze the clinical characteristics and risk factors of acute kidney injury (AKI) after hematopoietic stem cell transplantation (HCT) in children. The clinical data of children who underwent HCT a...
Browse all Complications after hematopoietic stem cell transplantation news →
Xiaohui Zhang, MD
Peking University People's Hospital
📍 TAMPA, FL
Xiaohui Zhang, MD, MD
Peking University People's Hospital
📍 Beijing, FL
Natalia Maximova, MD
Institute for Maternal and Child Health, IRCCS Burlo Garofalo, Trieste, Italy
Alice Bertaina, MD, MD, PhD
Stanford University
📍 PALO ALTO, CA
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Tobias Feuchtinger, Prof
Medical Center - University of Freiburg
View all Complications after hematopoietic stem cell transplantation specialists →